Autodesk To $260? Plus UBS Slashes PT On This Stock By 44%

Mizuho cut the price target on Splunk Inc. (NASDAQ: SPLK) from $110 to $100. Mizuho analyst Gregg Moskowitz maintained the stock with a Neutral rating. Splunk shares rose 2.6% to trade at $86.25 on Tuesday.
  • Mizuho cut the price target on Splunk Inc. (NASDAQ:SPLK) from $110 to $100. Mizuho analyst Gregg Moskowitz maintained the stock with a Neutral rating. Splunk shares rose 2.6% to trade at $86.25 on Tuesday.
  • Mizuho boosted the price target for Autodesk, Inc. (NASDAQ:ADSK) from $240 to $260. Autodesk shares rose 3.9% to trade at $232.04 on Tuesday.
  • UBS slashed the price target on MarketWise, Inc. (NASDAQ:MKTW) from $8 to $4.5. MarketWise shares rose 1.7% to trade at $2.40 on Tuesday.
  • BMO Capital cut the price target on Tyson Foods, Inc. (NYSE:TSN) from $90 to $75. Tyson Foods shares gained 1% to $65.44 on Tuesday.
  • Baird raised the price target for AECOM (NYSE:ACM) from $83 to $90. AECOM shares rose 0.8% to trade at $78.79 on Tuesday.

Check out this: Amazon Looking To Downsize, Here’s A Look At Recent Price Target Cuts By The Most Accurate Analysts

Total
0
Shares
Related Posts
Read More

IMV Announced Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S; IMV Expects Its Current Cash Position Will Be Sufficient To Fund Operations Into The Second Half of 2023

IMV Inc. (Nasdaq: IMV; TSX: IMV) today outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S (MVP-S). Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023 Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023

IMV